Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501253 | 1.00 | ADRB1 (0.46) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL2499131 | 0.86 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2497909 | 0.86 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2502887 | 0.84 | TRPA1 (0.45) | MAPTALDH1A1HTTPDE4APDE4B | |
| SCHEMBL2498022 | 0.84 | TRPA1 (0.45) | MAPTALDH1A1HTTPDE4APDE4B | |
| SCHEMBL3657826 | 0.84 | GAA (0.48) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL3653210 | 0.84 | GAA (0.48) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL4274415 | 0.84 | GAA (0.48) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL18110925 | 0.80 | HTT (0.56) | MAPTALDH1A1HTTPDE4APDE4B | |
| SCHEMBL18111591 | 0.80 | SMN1; SMN2 (0.48) | MAPTALDH1A1HTTGAATNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| CN-102083783-A | Substituted biphenyl GPR40 modulators | AMGEN INC | 2011-06-01 | — | — | CN | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ADRB1 59/4885ADRA2A 129/4885ADRB3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.